Shoshana Yakar
- ADJUNCT ASSOCIATE PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
Print Profile
Education
Ph.D., Tel-Aviv University
Postdoctoral Fellowship, National Institute of Diabetes and Digestive and Kidney Diseases
Research
Dr. Yakar is the co-Director of diabetes research in the Division of Endocrinology, Diabetes and Bone Disease. Her research focuses on the generation, development and use of various murine transgenic and knockout models related to the insulin-like growth factor 1 (IGF-1) signaling system. Dr. Yakar has received numerous awards from the Endocrine Society including The 2001 Molecular and Cellular Research Travel Award.
Publications
Shukla V, Coumoul X, Cao L, Wang RH, Xiao C, Xu X, Ando S, Yakar S, Leroith D, Deng C. Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res 2006 July; 66(14): 7151-7157.
Yakar S, Bouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwang D, Boisclair Y, Leroith D, Rosen CJ. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 2006 May; 189(2): 289-299.
Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S, Leroith D. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 2006 June; 147(6): 2616-2630.
Sadagurski M, Yakar S, Weingarten G, Holzenberger M, Rhodes CJ, Breitkreutz D, Leroith D, Wertheimer E. Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol 2006 April; 26(7): 2675-2687.
Samani AA, Yakar S, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2006 August;.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Yakar is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Room AB4-35
1428 Madison Avenue
New York, NY 10029
Fax: 212-241-7085
One Gustave L. Levy Place
Box 1055
New York, NY 10029
Fax: 212-241-4218